Spero Therapeutics Announces Positive Phase 3 PIVOT-PO Trial Results for Oral Tebipenem in Complicated Urinary Tract Infections at IDWeek 2025

Reuters

2025/10/14

Spero <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Positive Phase 3 PIVOT-PO Trial Results for Oral Tebipenem in Complicated Urinary Tract Infections at IDWeek 2025

Spero Therapeutics Inc., a clinical-stage biopharmaceutical company, announced upcoming presentations on its investigational oral carbapenem, tebipenem Hbr, at the IDWeek annual meeting taking place October 19-22, 2025, in Atlanta, GA. The presentations will include efficacy and safety results from the Phase 3 PIVOT-PO trial evaluating tebipenem Hbr in patients with complicated urinary tract infections (cUTI), including pyelonephritis. The oral presentation is scheduled for October 20, 2025. Additionally, poster presentations will cover the antibacterial spectrum and activity of tebipenem against Enterobacterales clinical isolates from the United States and United Kingdom, with results to be presented on October 21, 2025. These presentations are being made in collaboration with Spero's development partner, GSK.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spero Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9544842-en) on October 14, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2575972682"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575972682\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575972682?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-14 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575972682","market":"nz","top_or_hot":-1,"title":"Spero Therapeutics Announces Positive Phase 3 PIVOT-PO Trial Results for Oral Tebipenem in Complicated Urinary Tract Infections at IDWeek 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Spero <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Positive Phase 3 PIVOT-PO Trial Results for Oral Tebipenem in Complicated Urinary Tract Infections at IDWeek 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SPRO\">Spero Therapeutics Inc.</a>, a clinical-stage biopharmaceutical company, announced upcoming presentations on its investigational oral carbapenem, tebipenem Hbr, at the IDWeek annual meeting taking place October 19-22, 2025, in Atlanta, GA. The presentations will include efficacy and safety results from the Phase 3 PIVOT-PO trial evaluating tebipenem Hbr in patients with complicated urinary tract infections (cUTI), including pyelonephritis. The oral presentation is scheduled for October 20, 2025. Additionally, poster presentations will cover the antibacterial spectrum and activity of tebipenem against Enterobacterales clinical isolates from the United States and United Kingdom, with results to be presented on October 21, 2025. These presentations are being made in collaboration with Spero's development partner, GSK.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spero Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9544842-en) on October 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Spero Therapeutics Announces Positive Phase 3 PIVOT-PO Trial Results for Oral Tebipenem in Complicated Urinary Tract Infections at IDWeek 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSpero Therapeutics Announces Positive Phase 3 PIVOT-PO Trial Results for Oral Tebipenem in Complicated Urinary Tract Infections at IDWeek 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-14 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Spero <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Positive Phase 3 PIVOT-PO Trial Results for Oral Tebipenem in Complicated Urinary Tract Infections at IDWeek 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SPRO\">Spero Therapeutics Inc.</a>, a clinical-stage biopharmaceutical company, announced upcoming presentations on its investigational oral carbapenem, tebipenem Hbr, at the IDWeek annual meeting taking place October 19-22, 2025, in Atlanta, GA. The presentations will include efficacy and safety results from the Phase 3 PIVOT-PO trial evaluating tebipenem Hbr in patients with complicated urinary tract infections (cUTI), including pyelonephritis. The oral presentation is scheduled for October 20, 2025. Additionally, poster presentations will cover the antibacterial spectrum and activity of tebipenem against Enterobacterales clinical isolates from the United States and United Kingdom, with results to be presented on October 21, 2025. These presentations are being made in collaboration with Spero's development partner, GSK.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spero Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9544842-en) on October 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4112","symbol_name":"金融交易所和数据","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDLbfDNkx:1","article_id":"2575972682","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575972682","pubTimestamp":1760443260,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Spero Therapeutics Announces Positive Phase 3 PIVOT-PO Trial Results for Oral Tebipenem in Complicated Urinary Tract Infections at IDWeek 2025. Spero Therapeutics Inc., a clinical-stage biopharmaceutical company, announced upcoming presentations on its investigational oral carbapenem, tebipenem Hbr, at the IDWeek annual meeting taking place October 19-22, 2025, in Atlanta, GA. The presentations will include efficacy and safety results from the Phase 3 PIVOT-PO trial evaluating tebipenem Hbr in patients with complicated urinary tract infections , including pyelonephritis. The oral presentation is scheduled for October 20, 2025. Additionally, poster presentations will cover the antibacterial spectrum and activity of tebipenem against Enterobacterales clinical isolates from the United States and United Kingdom, with results to be presented on October 21, 2025. These presentations are being made in collaboration with Spero's development partner, GSK.Disclaimer: This news brief was created ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4112":"金融交易所和数据","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4139":"生物科技","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","SPRO":"Spero Therapeutics Inc.","BK4585":"ETF&股票定投概念","NDAQ":"纳斯达克OMX交易所","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4588":"碎股","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC"},"translate_title":"Spero Therapeutics在IDWeek 2025上宣布口服替比培南治疗复杂尿路感染的3期PIVOT-PO试验结果积极","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"SPRO":0.9},"content_text":"Spero Therapeutics Announces Positive Phase 3 PIVOT-PO Trial Results for Oral Tebipenem in Complicated Urinary Tract Infections at IDWeek 2025\n    \n\nSpero Therapeutics Inc., a clinical-stage biopharmaceutical company, announced upcoming presentations on its investigational oral carbapenem, tebipenem Hbr, at the IDWeek annual meeting taking place October 19-22, 2025, in Atlanta, GA. The presentations will include efficacy and safety results from the Phase 3 PIVOT-PO trial evaluating tebipenem Hbr in patients with complicated urinary tract infections (cUTI), including pyelonephritis. The oral presentation is scheduled for October 20, 2025. Additionally, poster presentations will cover the antibacterial spectrum and activity of tebipenem against Enterobacterales clinical isolates from the United States and United Kingdom, with results to be presented on October 21, 2025. These presentations are being made in collaboration with Spero's development partner, GSK.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spero Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9544842-en) on October 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}